Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trepibutone SCHEMBL25039 | 0.87 | TSHR (0.61) | TSHRHSD17B10CYP3A4ALDH1A1HPGD | |
| Trepibutone SCHEMBL29441541 | 0.87 | TSHR (0.61) | TSHRHSD17B10CYP3A4ALDH1A1HPGD | |
| SCHEMBL4264883 | 0.84 | KMT2A (0.53) | TSHRHSD17B10CYP3A4ALDH1A1CYP2C19 | |
| SCHEMBL5190414 | 0.83 | HMGCR (0.67) | HMGCRTSHRHSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL5518333 | 0.80 | HMGCR (0.53) | HMGCRTSHRHSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL11683269 | 0.79 | TSHR (0.51) | HMGCRTSHRHSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL16488700 | 0.77 | HMGCR (0.54) | HMGCRTSHRHSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL11833308 | 0.76 | HMGCR (0.49) | HMGCRTSHRHSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL28167915 | 0.75 | STING1 (0.54) | HMGCRTSHRHSD17B10CYP3A4ALDH1A1 | |
| SCHEMBL4264820 | 0.74 | TSHR (0.58) | TSHRHSD17B10ALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3943169-A | DIURETIC, SPASMOLYTIC | TAKEDA CHEMICAL INDUSTRIES, LTD (JA) | 1976-03-09 | — | — | US | claimed |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-119731195-A | Cyclic compounds having selective inhibition of KRAS over HRAS and NRAS | 中外制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| WO-2023214576-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| US-20230312147-A1 | APPARATUS, SYSTEM AND METHOD FOR FLUID DELIVERY | DEKA PRODUCTS LIMITED PARTNERSHIP | 2023-10-05 | — | — | US | disclosed |
| EP-4223755-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION INCLUDING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116456817-A | Heterocyclic compound and harmful arthropod control composition containing same | 住友化学株式会社 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022071428-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION INCLUDING SAME | 住友化学株式会社 | 2022-04-07 | — | — | WO | disclosed |
| US-20220063847-A1 | APPARATUS, SYSTEM AND METHOD FOR FLUID DELIVERY | DEKA PRODUCTS LIMITED PARTNERSHIP | 2022-03-03 | — | — | US | disclosed |
| US-4029699-A | CHOLERETIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-06-14 | — | — | US | disclosed |
| US-4017517-A | SPASMOLYTIC, CHOLERETIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-04-12 | — | — | US | disclosed |
| US-3943169-A | DIURETIC, SPASMOLYTIC | TAKEDA CHEMICAL INDUSTRIES, LTD (JA) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | HMGCR 2391/4885TSHR 3567/4885HSD17B10 2989/4885 |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | HMGCR 2391/4885TSHR 3567/4885HSD17B10 2989/4885 |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | PDCD1, CD274, PTPN1 | HMGCR 4032/4885TSHR 1675/4885HSD17B10 3715/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | HMGCR 2391/4885TSHR 3567/4885HSD17B10 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.